Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Pharma, Inc.BBIO · Entity 3360 | Director | June 22, 2026 | June 24, 2026 |
| CareDx, Inc.CDNA · Entity 4344 | Director | July 16, 2026 | July 17, 2026 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC.PACB · Entity 5650 | Director | June 03, 2026 | June 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Pharma, Inc.
Report date June 22, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,259 |
Ending reported balance
After 2026-06-23 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-06-22 · Grant · Acquired 3,990 · Balance 11,455 F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Row 2 · 2026-06-22 · Exercise / conversion · Acquired 2,808 · Balance 14,263 Row 3 · 2026-06-22 · Sale · Disposed 2,808 · Balance 11,455 F3: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 14, 2025. Row 4 · 2026-06-23 · Sale · Disposed 2,196 · Balance 9,259 F3: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 14, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.92 · Expires 2036-06-21 | Direct | 5,277 |
Reported balance
After 2026-06-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-06-22 · Grant · Acquired 5,277 · Balance 5,277 F4: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.73 · Expires 2035-06-19 | Direct | 5,617 |
Reported balance
After 2026-06-22 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-06-22 · Exercise / conversion · Disposed 2,808 · Balance 5,617 F5: One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 398 |
Reported balance
Holding disclosure · report date 2026-06-22 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 398 |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 14, 2025.
F4: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
F5: One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.
CareDx, Inc.
Report date July 16, 2026 · Filed July 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,686 |
Ending reported balance
After 2026-07-16 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-07-16 · Exercise / conversion · Acquired 7,606 · Balance 44,292 Row 2 · 2026-07-16 · Exercise / conversion · Acquired 16,048 · Balance 60,340 Row 3 · 2026-07-16 · Exercise / conversion · Acquired 5,125 · Balance 65,465 Row 4 · 2026-07-16 · Sale · Disposed 28,679 · Balance 36,786 F1: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.55 to $36.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 5 · 2026-07-16 · Sale · Disposed 100 · Balance 36,686 F1: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.56 · Expires 2032-06-15 | Direct | 0 |
Reported balance
After 2026-07-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-16 · Exercise / conversion · Disposed 7,606 · Balance 0 F3: The option is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.19 · Expires 2034-06-13 | Direct | 0 |
Reported balance
After 2026-07-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-07-16 · Exercise / conversion · Disposed 16,048 · Balance 0 F3: The option is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.96 · Expires 2033-06-15 | Direct | 24,011 |
Reported balance
After 2026-07-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-07-16 · Exercise / conversion · Disposed 5,125 · Balance 24,011 F3: The option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.55 to $36.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The option is fully vested.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.58 · Expires 2036-06-03 | Direct | 223,492 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 223,492 · Balance 223,492 F1: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 16, 2026 Filed Jul 17, 2026 20:22 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,125 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001855608-26-000004 · form4-07172026_080746.xml · derivative · entry 8 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,011 Underlying: Common Stock · 5,125 shares Expires 2033-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| July 16, 2026 Filed Jul 17, 2026 20:22 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,048 | $0.00 Strike: $14.19 | $0.00 |
DisclosureSEC source: 0001855608-26-000004 · form4-07172026_080746.xml · derivative · entry 7 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,048 shares Expires 2034-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| July 16, 2026 Filed Jul 17, 2026 20:22 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,606 | $0.00 Strike: $20.56 | $0.00 |
DisclosureSEC source: 0001855608-26-000004 · form4-07172026_080746.xml · derivative · entry 6 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,606 shares Expires 2032-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| July 16, 2026 Filed Jul 17, 2026 20:22 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 100 | $36.55 | $3,655.00 |
DisclosureSEC source: 0001855608-26-000004 · form4-07172026_080746.xml · nonDerivative · entry 5 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,686 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025. Read SEC document |
| July 16, 2026 Filed Jul 17, 2026 20:22 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 28,679 | $36.14 | $1,036,588.12 |
DisclosureSEC source: 0001855608-26-000004 · form4-07172026_080746.xml · nonDerivative · entry 4 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,786 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.55 to $36.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 16, 2026 Filed Jul 17, 2026 20:22 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 5,125 | $7.96 | $40,795.00 |
DisclosureSEC source: 0001855608-26-000004 · form4-07172026_080746.xml · nonDerivative · entry 3 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 16, 2026 Filed Jul 17, 2026 20:22 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 16,048 | $14.19 | $227,721.12 |
DisclosureSEC source: 0001855608-26-000004 · form4-07172026_080746.xml · nonDerivative · entry 2 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 16, 2026 Filed Jul 17, 2026 20:22 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 7,606 | $20.56 | $156,379.36 |
DisclosureSEC source: 0001855608-26-000004 · form4-07172026_080746.xml · nonDerivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 23, 2026 Filed Jun 24, 2026 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 2,196 | $68.57 | $150,579.72 |
DisclosureSEC source: 0001470831-26-000635 · wk-form4_1782338780.xml · nonDerivative · entry 4 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,259 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 14, 2025. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,808 | $0.00 Strike: $41.73 | $0.00 |
DisclosureSEC source: 0001470831-26-000635 · wk-form4_1782338780.xml · derivative · entry 7 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,617 Underlying: Common Stock · 2,808 shares Expires 2035-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 5,277 | $0.00 Strike: $68.92 | $0.00 |
DisclosureSEC source: 0001470831-26-000635 · wk-form4_1782338780.xml · derivative · entry 6 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,277 Underlying: Common Stock · 5,277 shares Expires 2036-06-21 F4 · derivative.exercise_date: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 2,808 | $68.00 | $190,944.00 |
DisclosureSEC source: 0001470831-26-000635 · wk-form4_1782338780.xml · nonDerivative · entry 3 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,455 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 14, 2025. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 2,808 | $41.73 | $117,177.84 |
DisclosureSEC source: 0001470831-26-000635 · wk-form4_1782338780.xml · nonDerivative · entry 2 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantCommon Stock | 3,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000635 · wk-form4_1782338780.xml · nonDerivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,455 F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 21:51 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 12,103 | $23.11 | $279,728.17 |
DisclosureSEC source: 0001855608-26-000003 · form4-06162026_090624.xml · nonDerivative · entry 2 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,686 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.00 to $23.30 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 21:51 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 9,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001855608-26-000003 · form4-06162026_090624.xml · nonDerivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,789 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), of which the RSUs vests 100% on the earlier of the one year anniversary of grant or the day immediately before the first Annual Meeting that occurs after the grant date., subject to the Reporting Person's continuous service on each applicable vesting date. Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 21:24 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 223,492 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001299130-26-000102 · wk-form4_1780608272.xml · derivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,492 Underlying: Common Stock · 223,492 shares Expires 2036-06-03 F1 · derivative.exercise_date: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:15 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,671 | $0.00 Strike: $27.36 | $0.00 |
DisclosureSEC source: 0001470831-26-000260 · wk-form4_1773346534.xml · derivative · entry 4 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,343 Underlying: Common Stock · 8,671 shares Expires 2034-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 21, 2024, such that all of the underlying shares will be vested on June 21, 2027, subject to the Reporting Person's continued service on the board of directors of the Issuer. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:15 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 8,671 | $72.00 | $624,312.00 |
DisclosureSEC source: 0001470831-26-000260 · wk-form4_1773346534.xml · nonDerivative · entry 2 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,465 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 14, 2025. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:15 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 8,671 | $27.36 | $237,238.56 |
DisclosureSEC source: 0001470831-26-000260 · wk-form4_1773346534.xml · nonDerivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:17 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,484 | $0.00 Strike: $48.45 | $0.00 |
DisclosureSEC source: 0001470831-26-000236 · wk-form4_1772572630.xml · derivative · entry 5 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,484 shares Expires 2031-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests and becomes exercisable in three annual installments after October 25, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:17 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 10,900 | $67.84 | $739,496.33 |
DisclosureSEC source: 0001470831-26-000236 · wk-form4_1772572630.xml · nonDerivative · entry 3 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,465 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 14, 2025. F3 · price: Represents the weighted average sale price of the shares sold from $67.42 to $68.31 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:17 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 14,584 | $67.08 | $978,284.51 |
DisclosureSEC source: 0001470831-26-000236 · wk-form4_1772572630.xml · nonDerivative · entry 2 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,365 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 14, 2025. F2 · price: Represents the weighted average sale price of the shares sold from $66.42 to $67.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:17 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 25,484 | $48.45 | $1,234,699.80 |
DisclosureSEC source: 0001470831-26-000236 · wk-form4_1772572630.xml · nonDerivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:50 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,484 | $0.00 Strike: $48.45 | $0.00 |
DisclosureSEC source: 0001470831-25-000317 · wk-form4_1763157038.xml · derivative · entry 4 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,484 Underlying: Common Stock · 25,484 shares Expires 2031-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vested and became exercisable in three annual installments after October 25, 2021. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:50 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 25,484 | $66.07 | $1,683,727.88 |
DisclosureSEC source: 0001470831-25-000317 · wk-form4_1763157038.xml · nonDerivative · entry 2 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,465 Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:50 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 25,484 | $48.45 | $1,234,699.80 |
DisclosureSEC source: 0001470831-25-000317 · wk-form4_1763157038.xml · nonDerivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 21:51 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 1,891 | $44.03 | $83,261.30 |
DisclosureSEC source: 0000950170-25-091762 · ownership.xml · nonDerivative · entry 4 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 398 Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 21:51 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 398 | $44.13 | $17,562.27 |
DisclosureSEC source: 0000950170-25-091762 · ownership.xml · nonDerivative · entry 3 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 2,289 F2 · price: Represents the weighted average sale price of the shares sold from $44.12 to $44.13 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 21:51 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 1,542 | $44.01 | $67,863.42 |
DisclosureSEC source: 0000950170-25-091762 · ownership.xml · nonDerivative · entry 2 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,465 Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 21:51 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 876 | $44.11 | $38,640.27 |
DisclosureSEC source: 0000950170-25-091762 · ownership.xml · nonDerivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,007 F1 · price: Represents the weighted average sale price of the shares sold from $44.025 to $44.14 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 22:55 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 8,425 | $0.00 Strike: $41.73 | $0.00 |
DisclosureSEC source: 0000950170-25-089643 · ownership.xml · derivative · entry 3 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,425 Underlying: Common Stock · 8,425 shares Expires 2035-06-19 F3 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 22:55 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantCommon Stock | 6,589 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-089643 · ownership.xml · nonDerivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,353 F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 20:30 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 10,570 | $19.16 | $202,565.59 |
DisclosureSEC source: 0000950170-25-089022 · ownership.xml · nonDerivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,994 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on December 12, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.62, inclusive. The reporting person undertakes to provide to CareDx, Inc., any security holder of CareDx, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4 Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 20:30 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 12,103 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-087412 · ownership.xml · nonDerivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,564 F1 · shares: The reported securities are represented by restricted stock units which shall vest in one installment on earlier of (i) June 13, 2026 or (ii) the day immediately prior to the first annual meeting of stockholders held by CareDx, Inc. after June 13, 2025. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 21:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (right to buy) · Derivative | 4,292 | $0.00 Strike: $16.75 | $0.00 |
DisclosureSEC source: 0000950170-25-084914 · ownership.xml · derivative · entry 4 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,334 Underlying: Common Stock · 4,292 shares Expires 2033-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 5, 2024. F2 · derivative.exercise_date: The stock option vests and becomes exercisable in three annual installments starting on June 22, 2023 and ending on June 22, 2025, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 21:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 4,292 | $40.00 | $171,680.00 |
DisclosureSEC source: 0000950170-25-084914 · ownership.xml · nonDerivative · entry 2 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,764 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 5, 2024. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 21:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 4,292 | $16.75 | $71,891.00 |
DisclosureSEC source: 0000950170-25-084914 · ownership.xml · nonDerivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 5, 2024. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:06 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001299130-25-000132 · wk-form4_1749240394.xml · derivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 20:43 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (right to buy) · Derivative | 12,875 | $0.00 Strike: $16.75 | $0.00 |
DisclosureSEC source: 0000950170-25-036420 · ownership.xml · derivative · entry 4 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,626 Underlying: Common Stock · 12,875 shares Expires 2033-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 5, 2024. F3 · derivative.exercise_date: The stock option vests in three annual installments starting on June 21, 2024 and ending on June 21, 2026, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 20:43 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 12,875 | $32.58 | $419,499.69 |
DisclosureSEC source: 0000950170-25-036420 · ownership.xml · nonDerivative · entry 2 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,764 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 5, 2024. F2 · price: Represents the weighted average sale price of the shares sold from $32.17 to $33.01 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 20:43 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 12,875 | $16.75 | $215,656.25 |
DisclosureSEC source: 0000950170-25-036420 · ownership.xml · nonDerivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,639 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 5, 2024. Read SEC document |
| June 21, 2024 Filed Jun 25, 2024 21:42 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 26,014 | $0.00 Strike: $27.36 | $0.00 |
DisclosureSEC source: 0000950170-24-077455 · ownership.xml · derivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,014 Underlying: Common Stock · 26,014 shares Expires 2034-06-20 F1 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 21, 2024, such that all of the underlying shares will be vested on June 21, 2027, subject to the Reporting Person's continued service on the board of directors of the Issuer. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 21:04 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 32,179 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001299130-24-000156 · wk-form4_1718917472.xml · derivative · entry 2 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,179 Underlying: Common Stock · 32,179 shares Expires 2034-06-18 F2 · derivative.exercise_date: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 21:04 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantCommon Stock | 22,821 | $0.00 | $0.00 |
DisclosureSEC source: 0001299130-24-000156 · wk-form4_1718917472.xml · nonDerivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,821 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU"). The RSUs will vest on the one (1) year anniversary of the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:43 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantStock Option (right to buy) · Derivative | 16,048 | $0.00 Strike: $9.35 | $0.00 |
DisclosureSEC source: 0000950170-24-074950 · ownership.xml · derivative · entry 2 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,048 Underlying: Common Stock · 16,048 shares Expires 2034-06-14 F2 · derivative.exercise_date: 1/12th of the shares subject to this option shall vest on July 14, 2024, and 1/12th of the shares subject to the option shall vest monthly thereafter through June 14, 2025. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:43 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 10,570 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-074950 · ownership.xml · nonDerivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,461 F1 · shares: The reported securities are represented by restricted stock units which shall vest in one installment on June 14, 2025. Read SEC document |
| June 14, 2024 Filed Jun 21, 2024 00:54 UTC Amendment | CareDx, Inc. CDNA · Entity 4344 | GrantStock Option (right to buy) · Derivative | 16,048 | $0.00 Strike: $14.19 | $0.00 |
DisclosureSEC source: 0000950170-24-075819 · ownership.xml · derivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,048 Underlying: Common Stock · 16,048 shares Expires 2034-06-14 F1 · derivative.exercise_price: This amendment is being filed to correct the exercise price of the derivative security of the Stock Option (right to buy) reported on the original Form 4. F2 · derivative.exercise_date: 1/12th of the shares subject to this option shall vest on July 14, 2024, and 1/12th of the shares subject to the option shall vest monthly thereafter through June 14, 2025. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 21:03 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (right to buy) · Derivative | 2,915 | $0.00 Strike: $8.45 | $0.00 |
DisclosureSEC source: 0000950170-24-017081 · ownership.xml · derivative · entry 4 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,261 Underlying: Common Stock · 2,915 shares Expires 2032-06-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 16, 2023. F2 · derivative.exercise_date: 1/3rd of the shares underlying the option vested on June 22, 2023; thereafter, 1/3rd of the underlying shares vest on an annual basis, so that all of the underlying shares will be vested on June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 21:03 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 2,915 | $37.75 | $110,041.25 |
DisclosureSEC source: 0000950170-24-017081 · ownership.xml · nonDerivative · entry 2 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,764 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 16, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.